Cancer cells can exploit these immune checkpoints to evade immune surveillance. By expressing high levels of checkpoint ligands like PD-L1, cancer cells can effectively "turn off" immune responses, allowing them to grow and proliferate without being attacked by the immune system. This immune evasion mechanism is a significant barrier to effective anti-tumor immunity.
